Targeted Cancer Drugs Tied to US Gut Toxicity

New study examines how cancer therapies can harm the digestive system and calls for greater collaboration between doctors to improve patient safety.

Published on Feb. 21, 2026

Got story updates? Submit your updates here. ›

A new paper published in Oncoscience examines how targeted cancer therapies, including tyrosine kinase inhibitors, antibody–drug conjugates, and CAR-T cell therapies, can cause distinct and sometimes serious digestive injuries that are often underrecognized. The authors analyzed clinical trials, FDA drug labels, national safety databases, and pathology reports, finding that these therapies can reduce blood vessel growth, damage intestinal lining cells, and trigger immune-related inflammation in the gastrointestinal tract. They highlight the importance of close collaboration between oncologists, gastroenterologists, and pathologists to ensure accurate diagnosis and better treatment decisions.

Why it matters

As the use of targeted cancer therapies expands, gastrointestinal toxicity has become an important clinical concern. These side effects can resemble other conditions, making them difficult to diagnose. Greater awareness and coordination between medical specialists is needed to support earlier diagnosis, better treatment, and improved patient protection.

The details

The paper outlines how different drug classes produce different patterns of injury. Tyrosine kinase inhibitors may reduce blood vessel growth in the gut, leading to diarrhea, abdominal pain, bleeding, or bowel perforation. Antibody–drug conjugates can damage normal intestinal lining cells, causing nausea, vomiting, mouth sores, and colitis. CAR-T cell therapy may trigger widespread immune-related inflammation that also affects the gastrointestinal tract. Biopsy samples may show cell death, ulceration, or inflammation, which can be misinterpreted without a clear treatment history.

  • The new paper was published in Volume 13 of Oncoscience on February 6, 2026.
  • The authors examined clinical trials, FDA drug labels, national safety databases, and pathology reports.

The players

Muhammad Moseeb Ali Hashim

The first author of the paper and a researcher at the University of Missouri-Columbia.

Kamran Zahoor

The co-corresponding author of the paper and a researcher at the University of Missouri-Columbia.

Got photos? Submit your photos here. ›

What’s next

The authors suggest that greater collaboration between oncologists, gastroenterologists, and pathologists is needed to ensure accurate diagnosis and better treatment decisions for patients experiencing gastrointestinal toxicity from targeted cancer therapies.

The takeaway

As precision oncology advances, coordinated care and informed monitoring will remain essential to keep these treatments both effective and safe for patients. Recognizing and managing gastrointestinal toxicity associated with targeted cancer therapies is crucial to improving patient outcomes.